Home ›
ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials ›
NCT07042581
A Study of Revaree Plus in People With Breast Cancer
The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.
Trial Details
NCT ID NCT07042581
Phase PHASE4
Sponsor Memorial Sloan Kettering Cancer Center
Status RECRUITING
Cancer Type ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
Locations (sample) Basking Ridge, New Jersey, United States|40.70621,-74.54932 Middletown, New Jersey, United States|40.39428,-74.11709 Montvale, New Jersey, United States|41.04676,-74.02292 Commack, New York, United States|40.84288,-73.29289 Harrison, New York, United States|40.96899,-73.71263
Key Eligibility Criteria
≥18 years of age at the time of signing informed consent. Stage 0-3 hormone-receptor positive breast cancer confirmed at MSKCC Able to complete study questionnaires in English or Spanish Breast cancer patients must have completed primary therapy (surgery, and/or chemotherapy, and/or radiation therapy) or currently on maintenance the…
For full eligibility, visit ClinicalTrials.gov .